Consensus $7.61. The company said, “This guidance includes an update to the company’s Pharmaceutical and Specialty Solutions segment profit outlook to 4% to 6% growth, from 1% to 3% growth. The company also updated its Global Medical Products and Distribution segment profit outlook to $140 million to $175 million, from approximately $175 million, primarily due to the impact of higher health and welfare costs. Additionally, the company updated expectations for its adjusted free cash flow to $1.0 billion to $1.5 billion, from approximately $1.0 billion.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Notable companies reporting before tomorrow’s open
- CAH Earnings this Week: How Will it Perform?
- Cardinal Health added to ‘Tactical Outperform’ list at Evercore ISI
- T2 Biosystems enters exclusive U.S. agreement with Cardinal Health
- Cardinal Health to acquire Integrated Oncology Network for $1.115B in cash